Previous 10 | Next 10 |
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to InflaRx's (NASDAQ:IFRX) vilobelimab to treat pyoderma gangrenosum (PG). PG is a rare disorder which causes large, painful ulcers to develop on the skin, often on the legs. The FDA grants orphan drug status to ...
The following slide deck was published by InflaRx N.V. in conjunction with this event. For further details see: InflaRx (IFRX) presents at H.C. Wainwright Global Investment Conference - Slideshow
JENA, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will give a company presentation at the upcoming H.C. Wainwri...
InflaRx press release (NASDAQ:IFRX): Q1 GAAP EPS of -€0.32. The company expects to initiate a Phase I program in the second half of 2022 and plans to study INF904 in complement-mediated, chronic autoimmune and inflammatory diseases where oral administration is the preferred choice for ...
Quarter highlighted by progress with vilobelimab in several indications : Encouraging Phase III topline results reported in patients with severe COVID-19; discussions with regulatory authorities already underway Final data from Phase IIa open-label study in patients with p...
Arcadia Biosciences (RKDA) -25% on Q4 results. UiPath (PATH) -19% on Q4 results. Clarus Therapeutics (CRXT) -18% on Q4 results. Sharecare (SHCR) -15% on Q4 results. InflaRx (IFRX) -13% vilobelimab fails to show statistical significance in seve...
InflaRx (NASDAQ:IFRX) said a phase 3 trial of vilobelimab in mechanically ventilated patients with COVID-19 did not show statistical significance in reducing risk of death. In the phase 3 part of the phase 2/3 study called PANAMO, vilobelimab treatment showed a relati...
Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show statistical significance on the pre-specified primary endpoint Pre-specified sensitivity analysis of the primary endpoint results in p-value...
InflaRx press release (NASDAQ:IFRX): FY GAAP EPS of -€1.10. cash and cash equivalents of €26.2 million For further details see: InflaRx GAAP EPS of -€1.10
Company received corrected FDA advice letter for Phase III trial with vilobelimab in hidradenitis suppurativa Positive Phase IIa data reported with vilobelimab in pyoderma gangrenosum; data being presented as late-breaker oral presentation at AAD Annual Meeting Topline data in vil...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...